Literature DB >> 3359606

Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen.

J Risteli1, S Niemi, P Trivedi, O Mäentausta, A P Mowat, L Risteli.   

Abstract

This is an equilibrium-type radioimmunoassay for the amino-terminal propeptide of type III procollagen (PIIINP), which overcomes the problem of nonparallelism between the standard and human serum samples encountered with earlier assays. Proper selection of antiserum and reaction conditions diminishes interference from degradation products of the propeptide in serum. Because a rapid solid-phase-bound second-antibody step is included, the assay takes only 3 h. The intra-assay and the interassay CVs are both about 5%. In infants and children the concentration of PIIINP in serum closely parallels the growth-velocity curve. For 88 presumably healthy adults, the PIIINP concentration was 1.7-4.2 micrograms/L, about a third that measured with the previously available commercial assay. This is because of lack of inhibition by small Col 1 domain-related degradation products.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359606

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  55 in total

1.  Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.

Authors:  P Garnero; M Piperno; E Gineyts; S Christgau; P D Delmas; E Vignon
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone.

Authors:  A Bojesen; N Birkebæk; K Kristensen; L Heickendorff; L Mosekilde; J S Christiansen; C H Gravholt
Journal:  Osteoporos Int       Date:  2010-07-24       Impact factor: 4.507

3.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

4.  Effect of dextran on synthesis, secretion and deposition of type III procollagen in cultured human fibroblasts.

Authors:  A Jukkola; J Risteli; L Risteli
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

5.  Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort.

Authors:  B Mazières; P Garnero; A Guéguen; M Abbal; L Berdah; M Lequesne; M Nguyen; J-P Salles; E Vignon; M Dougados
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

6.  A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide.

Authors:  C Heuck; L Heickendorff; O D Wolthers
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

7.  Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro.

Authors:  M Kassem; W Blum; J Ristelli; L Mosekilde; E F Eriksen
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

8.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

9.  N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone.

Authors:  Shalender Bhasin; E Jiaxiu He; Miwa Kawakubo; E Todd Schroeder; Kevin Yarasheski; Gregory J Opiteck; Alise Reicin; Fabian Chen; Raymond Lam; Jeffrey A Tsou; Carmen Castaneda-Sceppa; Ellen F Binder; Stanley P Azen; Fred R Sattler
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

10.  Transpulmonary gradient of type III procollagen peptides: acute effects of cardio-pulmonary bypass.

Authors:  N K Harrison; G J Laurent; T W Evans
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.